Publications 2009
1 Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in EuroSIDA. M van Luin, WP Bannister, A Mocroft, P Reiss, G Di Perri, G Peytavin, J Molto, A Karlsson, A Castagna, M Beniowski, JD Lundgren, DM Burger; the EuroSIDA study group
Antiviral Therapy. 2009;14(1):75-83. PMID: 19320239
2 Use of risk equations for predicting disease progression in HIV infection. A Mocroft, JD Lundgren.
Clin Infect Dis. editorial
3 Procalcitonin monitoring in trauma intensive care patients: how helpful is it? JU Jensen, JD Lundgren.
Critical Care Medicine 2009 Jun;37(6):2093-4. PubMed PMID: 19448450
4 Hepatitis C Virus (HCV) Coinfection Does Not Influence the CD4 Cell Recovery in HIV-1 Infected Patients with Maximum Virologic Suppression. L Peters, A Mocroft, V Soriano, J Rockstroh, P Aldins, M Losso, L Valerio, P Reiss, B Ledergerber, J Lundgren, for the EuroSIDA Study Group.
JAIDS. 2009 April;50(5):457-463.
5 Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. When to Start Consortium, J A Sterne, M May, D Costagliola, F De Wolf, A N Phillips, R Harris, M J Funk, R Geskus, J Gill, F Dabis, J M Miró, A Justice, B Ledergerber, G Fätkenheuer, R Hogg, A D'Arminio Monforte, M Saag, C Smith, S Staszewski, M Egger, S R Cole.
Lancet. 2009 Apr 18;373(9672):1352-63.Epub 2009 Apr 8. review. PubMed PMID:19361855; PubMed Central PMCID: PMC2670965. article
6 Major breakthroughs in the medical treatment of HIV infection.O Kirk, J Gerstoft, JD Lundgren, N Obel.
Ugeskr Laeger. 2009 Mar 2;171(10):787-789.full article
7 Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the DATA Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). SW Worm, S De Wit, R Weber, CA Sabin, P Reiss, W El-Sadr, AD Monforte, O Kirk, E Fontas, F Dabis, MG Law, JD Lundgren, N Friis-Møller.
Circulation. 2009 Feb 17;119(6):805-11. Epub 2009 Feb 2. article
8 Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D study). SW Worm, CA Sabin, P Reiss, W El-Sadr, A Monforte, C Pradier, R Thiebaut, M Law, M Richenbach, S De Wit, JD Lundgren, N Friis-Møller.
Diabetes Care. 2009 Mar;32(3):474-80. Epub 2008 Dec 3. article
9 Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. A M Kesselring, F W Wit, C A Sabin, J D Lundgren, J Gill, J Gatell, A Rauch, J S Montaner, F de Wolf, P Reiss, A Mocroft.
AIDS. 2009 Aug 24;23(13):1689-99.article
10 The ART Cohort Collaboration: Variable impact on mortality of AIDS defining events diagnosed during combination antiretroviral therapy: Not all AIDS Defining Conditions are Created Equal. Writing committee: Mocroft, A., Sterne, J., Egger, M., May, M., Grabar, S., Furrer, H., Sabin, C., Fatkenheuer, G., Justice, A., Reiss, P., d’Arminio Monforte, A., Gill, J., Hogg, R., Bonnet, F., Kitahata, M., Staszewski, S., Casabona, J., Harris, R. and Saag, M.
Clin Infect Dis. 2009 Apr 15;48(8):1138-51. PubMed PMID: 19275498.
11 Activation and Coagulation Biomarkers are Independent Predictors of the Development of Opportunistic Disease in Patients with HIV Infection. Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN; the INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group.
J Infect Dis. 2009 Sep 15;200(6):973-983. PubMed PMID:19678756.
12 Rate of Accumulation of Thymidine Analogue Mutations in Patients Continuing to
Receive Virologically Failing Regimens Containing Zidovudine or Stavudine: Implications for Antiretroviral Therapy Programs in Resource-Limited Settings. Cozzi-Lepri A, Phillips AN, Martinez-Picado J, d'Arminio Monforte A, Katlama C, Hansen AB, Horban A, Bruun J, Clotet B, Lundgren JD; EuroSIDA Study Group.
J Infect Dis. 2009 Sep 1;200(5):687-697. PubMed PMID: 19604043.
13 Cost-effectiveness of strategies for monitoring the response to antiretroviral therapy in resource-limited settings. Phillips AN, Gilks C, Lundgren JD.
Arch Intern Med. 2009 May 11;169(9):904; author reply 904-5. PubMed PMID:19433706.
14 Risk of virus transmission from well-treated patients with HIV? Gerstoft J, Mathiesen L, Lundgren JD, Nielsen HI, Pedersen C, Obel N, Laursen A.
Ugeskr Laeger. 2009 Mar 23;171(13):1085. Danish. PubMed PMID: 19321080.
15 Uncertainty as to whether the use of antiretroviral therapy for persons recently infected with HIV has a favorable risk-to-benefit ratio. Lundgren JD, Phillips AN, Neaton J.
Clin Infect Dis. 2009 Apr 15;48(8):1162; author reply 1162-3. PubMed PMID: 19292638.
16 Interruption of antiretroviral therapy is associated with increased plasma cystatin C. Mocroft A, Wyatt C, Szczech L, Neuhaus J, El-Sadr W, Tracy R, Kuller L, Shlipak M, Angus B, Klinker H, Ross M; INSIGHT SMART Study Group.
AIDS. 2009 Jan 2;23(1):71-82. PubMed PMID: 19050388.
17 Relative risk of death in the SMART study. B Grund, J Neuhaus, A Phillips; INSIGHT SMART Study Group.
Lancet Infect Dis. 2009 Dec;9(12):724-5.
18 Lipoprotein particle subclasses, cardiovascular disease and HIV infection. DA Duprez, LH Kuller, R Tracy, J Otvos, DA Cooper, J Hoy, J Neuhaus, NI Paton, N Friis-Møller, F Lampe, AP Liappis, JD Neaton for the INSIGHT SMART Study Group.
Atherosclerosis 2009; doi:10.1016/j.atherosclerosis.2009.05.001 (epub first).
19 Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group.
AIDS. 2009 Sep 24;23(15):2029-37.
20 Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. Podlekareva DN, Mocroft A, Post FA, Riekstina V, Miro JM, Furrer H, Bruyand M, Panteleev AM, Rakhmanova AG, Girardi E, Losso MH, Toibaro JJ, Caylá J, Miller RF, Obel N, Skrahina A, Chentsova N, Lundgren JD, Kirk O; HIV/TB Study Writing Group.
AIDS. 2009 Nov 27;23(18):2485-95. PubMed PMID: 19898216 article
21 Interleukin-2 therapy in patients with HIV infection. INSIGHT-ESPRIT Study Group; SILCAAT Scientific Committee, Abrams D, Lévy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S, Fox L, Gordin F, Lane HC, Lundgren JD, Mitsuyasu R, Neaton JD, Phillips A, Routy JP, Tambussi G, Wentworth D.
N Engl J Med. 2009 Oct 15;361(16):1548-59. PubMed PMID: 19828532 article
22 Incidence and risk factors of HIV-related non-Hodgkin lymphoma in the era of combination antiretroviral therapy: European multi-cohort study.The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group.
Antiviral Ther. 2009; 14(8):1065-74 article
23 Implementing the number needed to harm in clinical practice: risk of myocardial infarction in HIV-1-infected patients treated with abacavir. JD Kowalska, O Kirk, A Mocroft, L Høj, N Friis-Møller, P Reiss, I Weller, JD Lundgren.
HIV Medicine. Early View, October 2009. article (398K)
24 Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Antiretroviral Therapy Cohort Collaboration.
Int J Epidemiol. 2009 Dec;38(6):1624-33.
25 Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. Antiretroviral therapy cohort collaboration (ART-CC), Lanoy E, May M, Mocroft A, Phillip A, Justice A, Chêne G, Furrer H, Sterling T, Monforte AD, Force L, Gill J, Harris R, Hogg RS, Rockstroh J, Saag M, Khaykin P, de Wolf F, Sterne JA, Costagliola D.
AIDS. 2009 Oct 23;23(16):2199-208.
26 Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression. Moore DM, Harris R, Lima V, Hogg B, May M, Yip B, Justice A, Mocroft A, Reiss P, Lampe F, Chêne G, Costagliola D, Elzi L, Mugavero MJ, Monforte AD, Sabin C, Podzamczer D, Fätkenheuer G, Staszewski S, Gill J, Sterne JA; Antiretroviral Therapy Cohort Collaboration.
J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):357-63.
27 Continuous antiretroviral therapy decreases bone mineral density. Grund B, Peng G, Gibert CL, Hoy JF, Isaksson RL, Shlay JC, Martinez E, Reiss P, Visnegarwala F, Carr AD for the INSIGHT SMART body composition substudy group.
AIDS 2009; 23:1519-1529. article
28 Benefits and burdens of participation in a longitudinal clinical trial. Lazovski J, Losso M, Krohmal B, Emanuel EJ, Grady C, Wendler D for the ESPRIT Study/Group.
J Empir Res Hum Res Ethics 2009; 4(3):89-97.
Updated: 18 Oct 2010